Literature DB >> 18982322

Modification of primers for GRHPR genotyping: avoiding allele dropout by single nucleotide polymorphisms and homology sequence.

Naohisa Takaoka1, Tatsuya Takayama, Miki Miyazaki, Masao Nagata, Seiichiro Ozono.   

Abstract

Mutation of primer site for genotyping by polymerase chain reaction (PCR) may cause allele dropout and other genotyping failures. Primary hyperoxaluria type 2 (PH2) is a rare inherited disease caused by overproduction of endogenous oxalate due to mutations in the glyoxylate/hydroxypyruvate reductase (GRHPR) gene. Here, to avoid allele dropout and primer annealing to multiple sites, and given the discrepancy in intron length between GRHPR gene data, we updated the primers used in the sequence assay of the GRHPR gene. These redesigned primers show potential in reducing detection failure of GRHPR mutations. In addition, we performed a single nucleotide polymorphism (SNP) linkage analysis of the GRHPR gene using direct sequencing with PCR amplification of specific alleles (DS-PASA). Using this technique, we sequenced four common SNPs between intron E and exon 6, which show linkage disequilibrium (LD) consisting of three types of haplotypes, similar to data from the HapMap SNP database.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18982322     DOI: 10.1007/s00240-008-0159-z

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  20 in total

1.  A haplotype map of the human genome.

Authors: 
Journal:  Nature       Date:  2005-10-27       Impact factor: 49.962

2.  Haplotyping by double PCR amplification of specific alleles.

Authors:  G Sarkar; S S Sommer
Journal:  Biotechniques       Date:  1991-04       Impact factor: 1.993

3.  Allelic dropout in long QT syndrome genetic testing: a possible mechanism underlying false-negative results.

Authors:  David J Tester; Lisa B Cronk; Janet L Carr; Vincent Schulz; Benjamin A Salisbury; Richard S Judson; Michael J Ackerman
Journal:  Heart Rhythm       Date:  2006-03-16       Impact factor: 6.343

4.  Kinetic analysis and tissue distribution of human D-glycerate dehydrogenase/glyoxylate reductase and its relevance to the diagnosis of primary hyperoxaluria type 2.

Authors:  C F Giafi; G Rumsby
Journal:  Ann Clin Biochem       Date:  1998-01       Impact factor: 2.057

5.  Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS).

Authors:  C R Newton; A Graham; L E Heptinstall; S J Powell; C Summers; N Kalsheker; J C Smith; A F Markham
Journal:  Nucleic Acids Res       Date:  1989-04-11       Impact factor: 16.971

6.  Distribution of human SNPs and its effect on high-throughput genotyping.

Authors:  Daniel C Koboldt; Raymond D Miller; Pui-Yan Kwok
Journal:  Hum Mutat       Date:  2006-03       Impact factor: 4.878

7.  Identification of missense, nonsense, and deletion mutations in the GRHPR gene in patients with primary hyperoxaluria type II (PH2).

Authors:  K E Webster; P M Ferree; R P Holmes; S D Cramer
Journal:  Hum Genet       Date:  2000-08       Impact factor: 4.132

8.  Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2.

Authors:  David P Cregeen; Emma L Williams; Sally Hulton; Gill Rumsby
Journal:  Hum Mutat       Date:  2003-12       Impact factor: 4.878

9.  Allele dropout in PCR-based diagnosis of Wilson disease: mechanisms and solutions.

Authors:  Ching-Wan Lam; Chloe M Mak
Journal:  Clin Chem       Date:  2006-03       Impact factor: 8.327

Review 10.  A novel method for detecting point mutations or polymorphisms and its application to population screening for carriers of phenylketonuria.

Authors:  S S Sommer; J D Cassady; J L Sobell; C D Bottema
Journal:  Mayo Clin Proc       Date:  1989-11       Impact factor: 7.616

View more
  1 in total

1.  Association between polymorphisms in osteopontin gene (SPP1) and first episode calcium oxalate urolithiasis.

Authors:  Mohammad Reza Safarinejad; Nayyer Shafiei; Shiva Safarinejad
Journal:  Urolithiasis       Date:  2013-06-20       Impact factor: 3.436

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.